Has John Khoury, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,353,057 in general payments to John Khoury, MD across 1,708 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Khoury, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Khoury, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Khoury, MD

Neurology · Abington, PANPI 1255549713

Payments from drug & device makers

$1,353,057in general payments, 2019–2025

Across 1,708 payments — averaging $792.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$1.1M
Harmony Biosciences LLC$106K
Axsome Therapeutics, Inc.$57K
Alkermes, Inc.$51K
Eisai Inc.$31K
Avadel CNS Pharmaceuticals, LLC$14K
plus $28K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	1,014	$1,065,666
Harmony Biosciences LLC	84	$105,810
Axsome Therapeutics, Inc.	76	$56,974
Alkermes, Inc.	55	$51,427
Eisai Inc.	46	$31,496
Avadel CNS Pharmaceuticals, LLC	45	$14,105
Lilly USA, LLC	10	$9,484
AstraZeneca(2 entities)	72	$4,764
Merck	16	$2,582
Eisai CO., LTD.	1	$2,420
Idorsia Pharmaceuticals US Inc	3	$1,755
AbbVie(2 entities)	32	$755
Argenx US, Inc.	23	$664
Amgen	10	$643
Inspire Medical Systems, Inc.	13	$441
Teva Pharmaceuticals USA, Inc.	17	$410
Supernus Pharmaceuticals, Inc.	33	$384
UCB, Inc.	21	$353
Pfizer	12	$239
SK Life Science, Inc.	7	$176
Amneal Pharmaceuticals LLC	9	$145
Neurelis, Inc.	3	$140
Genentech USA, Inc.	2	$121
Sanofi	2	$117
Lundbeck LLC	6	$112
Bristol Myers Squibb	1	$104
Sunovion Pharmaceuticals Inc.	6	$101
Johnson & Johnson	1	$98
Biogen	3	$89
CSL Behring	4	$86
Avion Pharmaceuticals	5	$82
Kyowa Kirin, Inc.	5	$80
Sumitomo Pharma America, Inc.	6	$77
Arbor Pharmaceuticals, Inc.	5	$70
Currax Pharmaceuticals LLC	4	$63
Impel Pharmaceuticals LLC	3	$57
EMD Serono, Inc.	3	$55
Resmed Corp	3	$55
Merz Pharmaceuticals, LLC	3	$55
Boston Scientific	3	$52
Tersera Therapeutics LLC	4	$50
Greenwich Biosciences, Inc.	3	$50
Mallinckrodt Hospital Products Inc.	1	$44
Abbott	2	$44
Otsuka America Pharmaceutical, Inc.	2	$44
Novartis	2	$41
Upsher-smith Laboratories LLC	2	$40
Biohaven Pharmaceuticals, Inc.	3	$40
Grifols USA, LLC	2	$40
Neurocrine Biosciences, Inc.	2	$33
Springworks Therapeutics, Inc.	1	$30
Tanabe Pharma America, Inc.	2	$30
Catalyst Pharmaceuticals, Inc.	2	$30
Aucta Pharmaceuticals, Inc.	1	$26
Hoffmann-la Roche Limited	1	$25
Alnylam Pharmaceuticals Inc.	1	$25
Vertical Pharmaceuticals, LLC	2	$24
Acorda Therapeutics, Inc	1	$22
Banner Life Sciences, LLC	1	$21
Aquestive Therapeutics, Inc.	1	$18

How this compares

$1,353,057 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$2,644,488

Medicare patients

832

Services billed

486,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Abington

David WeismanAbington$9.3M
Brad KleinAbington$1.2M
Amit Bar-OrPhiladelphia$7.7M
Thomas LeistPhiladelphia$5.8M
Jan DrappatzPittsburgh$4M
Lauren ElmanPhiladelphia$3.3M
David IrwinPhiladelphia$2.5M
Paula ClemensPittsburgh$2.1M
Anoopum GuptaPittsburgh$2M
Daniel KremensPhiladelphia$1.9M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →